A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)

Meeting abstrac

Age and gender effects on the diagnostic power of the DST

Among 365 major and 158 minor depressive impatients, the dexamethasone suppression test (DST) yielded an overall diagnostic sensitivity of 50%, a specificity of 85%, and a confidence level of 88%. Age was significantly correlated with the post-dexamethasone cortisol levels in the whole sample (r = 0.11; P < 0.01); however, this low relationship disappeared when all subgroups defined by gender or diagnostic were considered. Gender did not appear to influence DST results; however, among the patients between 30 and 39 years, the diagnostic performance of the DST was significantly lower among female as compared to male patients, suggesting possible interferences with endocrine variables. © 1987.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Constructing ‘Englishness’ and promoting ‘politeness’ through a ‘Francophobic’ bestseller: Télémaque

This article draws attention to the reception that Fran\ue7ois F\ue9nelon's T\ue9l\ue9maque (1699) received in England in the first half of the eighteenth century. It overturns the historiographical assumption that the Jacobites were the leading disseminators of this continental bestseller on the other side of the Channel. Even though in the English intellectual context T\ue9l\ue9maque's framework was unorthodox, many staunch supporters of the Glorious Revolution were fascinated by the book's portrayal of a virtuous king who respects laws, rights and liberties, and sacrifices himself to improve the wellbeing of his subjects. Moderate Whigs - who included several Huguenot refugees - capitalised on the poem's esprit du roi in order both to celebrate the English kings and to construct the \u2018Myth of Louis XIV' as an example of how a sovereign should not rule. The study of the book's reception thus presents a somewhat emblematic case study from which to view the genesis of \u2018Englishness', that of an ideological discourse largely based on a process of overturning. In addition, the T\ue9l\ue9maque responded to the thirst for \u2018useful Knowledge' that distinguished the advocates of \u2018politeness' and, not least, its mild pedagogical approach rendered it a precious resource for the \u2018moderation\u2019 of the youth

Premières communautés paysannes en Méditerranée occidentale

La transition de l’économie de chasse-cueillette à l’économie agricole en Méditerranée centrale et occidentale s’effectue essentiellement entre le VIIe et le IVe millénaire avant J.-C. Cette période voit s’implanter un type d’économie totalement neuf, générateur de mutations rapides et souvent irréversibles au plan de l’environnement. À ce titre les mutations de cette période jouent un rôle essentiel dans l’évolution ultérieure des sociétés et de leur cadre de vie et participent au fondement même du monde rural protohistorique et historique. C’est la première fois que de la mer Égée au Portugal et à la façade atlantique de l’Europe sont confrontés les résultats de nombreux spécialistes relevant de plusieurs disciplines, qu’ils soient archéologues, physiciens, géographes ou palynologues, anthracologistes, faunistes, sédimentologues ou pétrographes. Au cours de ce Colloque la genèse du monde rural a été traitée, autant que possible, dans la totalité de ses aspects : chronologie, variation des niveaux marins, mutations de l’environnement, impacts humains sur le paysage et les sols, caractères des premiers élevages, débuts de l’agriculture, circulation des matériaux, diversité des expressions culturelles de l’Égée et de l’Adriatique jusqu’à l’Atlantique.Responsables: Jean GUILAINE, Directeur de Recherche a u C.N.R.S., Directeur d’Études à l’E.H.E.S.S. (ER 289, Toulouse). Jean COURTIN, Directeur de Recherche a u C.N.R.S., Directeur des Antiquités Préhistoriques de Provence (ER 46, Marseille). Jean-Louis ROUDIL, Chargé de Recherche a u C.N.R.S., Directeur des Antiquités Préhistoriques de Languedoc-Roussillon (ER 46, Marseille). Jean-Louis VERNET, Professeur à l’Université des Sciences et Techniques du Languedoc, Directeur de la R.C.P. 576 (Montpellier). Comité d’organisation: Les Responsables et: Alain BEECHING, Chargé de Recherche a u C.N.R.S. Didier BINDER, Chargé de Recherche au C.N.R.S. Françoise CLAUSTRE, Chargée de Recherche a u C.N.R.S. André D’ANNA, Chargé de Recherche a u C.N.R.S. Henri DUDAY, Chargé de Recherche au C.N.R.S. Jean GASCO, Chargé de Recherche a u C.N.R.S. Xavier GUTHERZ, Directeur-Adjoint des Antiquités du Languedoc. Jean VAQUER, Chargé de Recherche au C.N.R.S. Collaborateurs : Jacques ABADIE, Jacques AIGOUIN, Catherine AMIEL, François BRIOIS, Isabelle CARRERE, Lucie CHABAL, Albert COLOMER, Jacques COULAROU, Christian LE DECHAULT DE MONTRE-DON, Christiane GUILAINE, Christine HEINZ, Jacques PITHIOUD, Carol RIVENQ, Magdeleine ROBERT

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

International audienceBackground: Various observations have suggested that the course of COVID-19 might be less favourable in patients with inflammatory rheumatic and musculoskeletal diseases receiving rituximab compared with those not receiving rituximab. We aimed to investigate whether treatment with rituximab is associated with severe COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases.Methods: In this cohort study, we analysed data from the French RMD COVID-19 cohort, which included patients aged 18 years or older with inflammatory rheumatic and musculoskeletal diseases and highly suspected or confirmed COVID-19. The primary endpoint was the severity of COVID-19 in patients treated with rituximab (rituximab group) compared with patients who did not receive rituximab (no rituximab group). Severe disease was defined as that requiring admission to an intensive care unit or leading to death. Secondary objectives were to analyse deaths and duration of hospital stay. The inverse probability of treatment weighting propensity score method was used to adjust for potential confounding factors (age, sex, arterial hypertension, diabetes, smoking status, body-mass index, interstitial lung disease, cardiovascular diseases, cancer, corticosteroid use, chronic renal failure, and the underlying disease [rheumatoid arthritis vs others]). Odds ratios and hazard ratios and their 95% CIs were calculated as effect size, by dividing the two population mean differences by their SD. This study is registered with ClinicalTrials.gov, NCT04353609.Findings: Between April 15, 2020, and Nov 20, 2020, data were collected for 1090 patients (mean age 55·2 years [SD 16·4]); 734 (67%) were female and 356 (33%) were male. Of the 1090 patients, 137 (13%) developed severe COVID-19 and 89 (8%) died. After adjusting for potential confounding factors, severe disease was observed more frequently (effect size 3·26, 95% CI 1·66-6·40, p=0·0006) and the duration of hospital stay was markedly longer (0·62, 0·46-0·85, p=0·0024) in the 63 patients in the rituximab group than in the 1027 patients in the no rituximab group. 13 (21%) of 63 patients in the rituximab group died compared with 76 (7%) of 1027 patients in the no rituximab group, but the adjusted risk of death was not significantly increased in the rituximab group (effect size 1·32, 95% CI 0·55-3·19, p=0·53).Interpretation: Rituximab therapy is associated with more severe COVID-19. Rituximab will have to be prescribed with particular caution in patients with inflammatory rheumatic and musculoskeletal diseases

Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

International audienceObjectives: There is little known about the impact of SARS-CoV-2 on patients with inflammatory rheumatic and musculoskeletal diseases (iRMD). We examined epidemiological characteristics associated with severe disease, then with death. We also compared mortality between patients hospitalised for COVID-19 with and without iRMD.Methods: Individuals with suspected iRMD-COVID-19 were included in this French cohort. Logistic regression models adjusted for age and sex were used to estimate adjusted ORs and 95% CIs of severe COVID-19. The most significant clinically relevant factors were analysed by multivariable penalised logistic regression models, using a forward selection method. The death rate of hospitalised patients with iRMD-COVID-19 (moderate-severe) was compared with a subset of patients with non-iRMD-COVID-19 from a French hospital matched for age, sex, and comorbidities.Results: Of 694 adults, 438 (63%) developed mild (not hospitalised), 169 (24%) moderate (hospitalised out of the intensive care unit (ICU) and 87 (13%) severe (patients in ICU/deceased) disease. In multivariable imputed analyses, the variables associated with severe infection were age (OR=1.08, 95% CI: 1.05-1.10), female gender (OR=0.45, 95% CI: 0.25-0.80), body mass index (OR=1.07, 95% CI: 1.02-1.12), hypertension (OR=1.86, 95% CI: 1.01-3.42), and use of corticosteroids (OR=1.97, 95% CI: 1.09-3.54), mycophenolate mofetil (OR=6.6, 95% CI: 1.47-29.62) and rituximab (OR=4.21, 95% CI: 1.61-10.98). Fifty-eight patients died (8% (total) and 23% (hospitalised)). Compared with 175 matched hospitalised patients with non-iRMD-COVID-19, the OR of mortality associated with hospitalised patients with iRMD-COVID-19 was 1.45 (95% CI: 0.87-2.42) (n=175 each group).Conclusions: In the French RMD COVID-19 cohort, as already identified in the general population, older age, male gender, obesity, and hypertension were found to be associated with severe COVID-19. Patients with iRMD on corticosteroids, but not methotrexate, or tumour necrosis factor alpha and interleukin-6 inhibitors, should be considered as more likely to develop severe COVID-19. Unlike common comorbidities such as obesity, and cardiovascular or lung diseases, the risk of death is not significantly increased in patients with iRMD

Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

International audienceObjectives: There is little known about the impact of SARS-CoV-2 on patients with inflammatory rheumatic and musculoskeletal diseases (iRMD). We examined epidemiological characteristics associated with severe disease, then with death. We also compared mortality between patients hospitalised for COVID-19 with and without iRMD.Methods: Individuals with suspected iRMD-COVID-19 were included in this French cohort. Logistic regression models adjusted for age and sex were used to estimate adjusted ORs and 95% CIs of severe COVID-19. The most significant clinically relevant factors were analysed by multivariable penalised logistic regression models, using a forward selection method. The death rate of hospitalised patients with iRMD-COVID-19 (moderate-severe) was compared with a subset of patients with non-iRMD-COVID-19 from a French hospital matched for age, sex, and comorbidities.Results: Of 694 adults, 438 (63%) developed mild (not hospitalised), 169 (24%) moderate (hospitalised out of the intensive care unit (ICU) and 87 (13%) severe (patients in ICU/deceased) disease. In multivariable imputed analyses, the variables associated with severe infection were age (OR=1.08, 95% CI: 1.05-1.10), female gender (OR=0.45, 95% CI: 0.25-0.80), body mass index (OR=1.07, 95% CI: 1.02-1.12), hypertension (OR=1.86, 95% CI: 1.01-3.42), and use of corticosteroids (OR=1.97, 95% CI: 1.09-3.54), mycophenolate mofetil (OR=6.6, 95% CI: 1.47-29.62) and rituximab (OR=4.21, 95% CI: 1.61-10.98). Fifty-eight patients died (8% (total) and 23% (hospitalised)). Compared with 175 matched hospitalised patients with non-iRMD-COVID-19, the OR of mortality associated with hospitalised patients with iRMD-COVID-19 was 1.45 (95% CI: 0.87-2.42) (n=175 each group).Conclusions: In the French RMD COVID-19 cohort, as already identified in the general population, older age, male gender, obesity, and hypertension were found to be associated with severe COVID-19. Patients with iRMD on corticosteroids, but not methotrexate, or tumour necrosis factor alpha and interleukin-6 inhibitors, should be considered as more likely to develop severe COVID-19. Unlike common comorbidities such as obesity, and cardiovascular or lung diseases, the risk of death is not significantly increased in patients with iRMD